During a gathering of clinicians, scientists and economists at this year's Medical Technology Congress (Treffpunkt für Medizintechnik) held in Berlin's Charité Hospital, all 17 lectures focused on cancer treatments. Bettina Döbereiner reports
Barcelona, Spain 26-29 November
Dresden, Germany 16-19 September
Completion of a Phase I clinical trial has demonstrated the great promise of a completely new type of cancer treatment, according to results announced this June in The New England Journal of Medicine by scientists at the Institute of Cancer Research (ICR) and the Royal Marsden Hospital in the United Kingdom, working with pharma firm AstraZeneca.
Positive CB7630 (Abiraterone Acetate) Phase II Data was presented at the ASCO Annual Meeting in Chicago this May/June, Cougar Biotechnology Inc, a development stage biopharmaceutical firm with a specific focus on oncology. In mid-July, Johnson & Johnson announced its acquisition of Cougar, which is now working with Ortho Biotech Oncology Research & Development, a division of the J&J firm Centocor…
PSA-Kritiker PD Dr. rer. nat. Hans-Hermann Dubben und DGU-Generalsekretär Prof. Dr. Michael Stöckle suchten das Gespräch Selten wurde zwischen den Kritikern und den Befürwortern der PSA-gestützten Früherkennung des Prostatakarzinoms so hart diskutiert. Die Veröffentlichung der randomisierten Studien zum PSA-Screening aus Europa (ERSPC-Studie) und den USA (PLCO-Screeningstudie) hatte in…
Tissue removal is currently the only way to verify suspicious lesions in the prostate. It is also a key requirement before treating prostate carcinomas. The standard biopsy is performed with transrectal ultrasound (TRUS) to guide the needle in the right direction.
IMRT is an evolving method of treatment for complex forms of cancer. Although patients benefit from treatment, a precise evaluation of that benefit and overall cost-effectiveness of the method is still an uncertain science. Mark Nicholls reports
Training is critical to the further development of urology across Europe, yet urologists recognise there are gaps in this; so much so that the European Society of Urological Technology (ESUT) has restructured with an emphasis on training to meet the demands and challenges ahead. Mark Nicholls reports.
To date, there is insufficient knowledge as to the cause of this disease, or how to prevent it. We asked some of our EH correspondents to report on measures taken in their countries to ensure that men are made more aware of this disease and whether screening services are provided for early prostate cancer detection.
Current procedures are still imprecise and speculative; without a subsequent biopsy suspicious PSA levels, images and the results of palpation cannot be correctly evaluated. Thus there is an energetic pursuit to discover new imaging technologies. Dr Thilo Eggert at the Urological Clinic of the Ruhr University Bochum at the Marienhopital Herne, is among the investigators.
17-21 March Stockholm Sweden
To date, there is insufficient knowledge as to the cause of this disease, or how to prevent it. We asked some of our EH correspondents to report on measures taken in their countries to ensure that men are made more aware of this disease and whether screening services are provided for early prostate cancer detection.
A potential biomarker for cancer has been identified in urine.
We asked some of our EH correspondents to report on measures taken in their countries to ensure that men are made more aware of this disease and whether screening services are provided for early prostate cancer detection.
Big discussions are expected at the upcoming European Association of Urology (EAU) Congress in Stockholm* when urologist Dr Jochen Walz (right), of the Urological Department at the Institute Paoli-Calmettes, Marseilles, France, presents the forum: Imaging in Europe: Who, where, what, how many! and M F Coelho, of the European Society of Urological Imaging (ESUI) describes the Clinical utility of…
GE Healthcare's first Discovery PET/CT 600-series scanners are being installed in a number of leading clinics around the world. "This first set of installations is a big step forward in the diagnosis and monitoring of disease", said Terri Bresenham, newly appointed vice- president and general manager of GE Healthcare's global Molecular Imaging business.
Accreditation and standards of Excellence in Europe
The number of prostate cancer cases is increasing rapidly.
To date, there is insufficient knowledge as to the cause of this disease, or how to prevent it. We asked some of our EH correspondents to report on measures taken in their countries to ensure that men are made more aware of this disease and whether screening services are provided for early prostate cancer detection.
Cancer may well surpass cardiovascular diseases as the primary case of death in Europe by 2012. To prevent this from happening, cancer therapeutics have to shift in focus from the treatment of symptoms to offering a total cure, despite the complex, multifactorial nature of cancer indications.
An estimated 6.7 million people in developed countries were diagnosed with cancer in 2007. Delivering their care is no easy matter. Tele-oncology, the remote provision of oncology services, could not only reduce the costs of consultations for cancer departments, but also for patients. Kerry Heacox, of i.t. Communications, reports on the success of remote consultations in Labrador and Newfoundland.…
The University of Pittsburgh Medical Center and GE Healthcare plan to establish over 25 local cancer centres in various countries within the coming decade.
Early suspicions of cancer, either from clinical evidence or medical imaging, are often followed up on biopsy. However, the removal of tissue for histological analysis can be uncomfortable for patients.
Currently, early detection of Prostate Cancer depends on an abnormal digital rectal examination and an elevated prostate-specific-antigen (PSA) level requiring a prostate biopsy, often associated with anxiety, discomfort, complications, and heavy expenses. The prostate-cancer-gene-3 (PCA3) test is a new PCa gene-based marker carried out with a urine sample.